Skip to main content

Novel Rx

Psoriasis, arms, PsA

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

Jan 12, 2022

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

Read Article
Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/GxmgWIbgSo

Dr. John Cush @RheumNow( View Tweet )

Jan 11, 2022
Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

Jan 11, 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.



This was a phase II, dose-finding trial, aimed to assess

Read Article
IV,arm,intravenous,infusion

BEAT LUPUS - Belimumab after Rituximab in SLE

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article
2021,year

2021 Rheumatology Year in Review

Jan 08, 2022

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit!https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c
Dr. John Cush @RheumNow( View Tweet )
Jan 07, 2022
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka
Dr. John Cush @RheumNow( View Tweet )
Jan 05, 2022
Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/ZQDvl6AaZz

Dr. John Cush @RheumNow( View Tweet )

Jan 03, 2022
RheumNow Podcast square

Best of 2021: Jack of All Subspecialties

Dec 31, 2021

It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen

Read Article
FDA.Safety.jpg

Best of 2021: FDA Puts Boxed Warnings on JAK Inhibitors

Dec 30, 2021

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before

Read Article
COVID vaccine vials

Best of 2021: Comparison of Three Coronavirus Vaccines

Dec 30, 2021

On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available.  We've compiled a comparison table and some key information relevant to your

Read Article
RheumNow Podcast square

Best of 2021: Tofacitinib Safety Concerns

Dec 29, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
COVID vaccine vials

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a broad scale, has

Read Article
Stiffness,hand,MCP,joint,pain

Best of 2021: 11 Drugs That Cause Arthritis

Dec 27, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as the aching are asking, they are really thinking these joint complaints must be due to something.

Read Article
Registration now open for RheumNow Live! Join us March 19-20 in Irving, TX or virtually!https://t.co/py6Gp8sPh8

Dr. John Cush @RheumNow( View Tweet )

Dec 24, 2021
FDA.approved.jpg

Best of 2021: FDA Approves Anifrolumab in SLE

Dec 24, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  



Saphnelo the 

Read Article
Download your RheumaKnowledgy Card https://t.co/GauMzCH5lB https://t.co/CrS7r6RAoc

Dr. John Cush @RheumNow( View Tweet )

Dec 22, 2021
Lungs ILD

Best of 2021: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Dec 21, 2021

Genentech announced March 4th that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
FDA.approved.jpg

Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis

MedPage Today
Dec 15, 2021

The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced on Tuesday.



Tofacitinib is

Read Article
FDA%20approved.jpg (keep)

Rinvoq FDA Approved for Active Psoriatic Arthritis

Dec 14, 2021

The FDA has approved upadacitinib (Rinvoq) today for use in the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.



The FDA approval is based on two pivotal Phase 3 trials,

Read Article
COVID Test Antibody

Serious Adverse Events Associated with Tocilizumab in COVID-19 Patients

Dec 14, 2021

Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.



Tocilizumab, an interleukin-6 receptors monoclonal antibody, is currently authorized for emergency treatment of

Read Article
pill pillbox adherence

Adherence to Medication - Predictive Factors in RA

Dec 13, 2021

The numbers on treatment adherence is disappointingly low in RA, with a number of psychological, communication and logistical factors that outweigh the potentially negative influence of sociodemographic or clinical factors.



A 6-month prospective cohort study of RA patients assessed

Read Article
ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC
Dr. John Cush @RheumNow( View Tweet )
Dec 10, 2021
BMS has announced they have filed a new drug application with the FDA and EMA for Deucravacitinib, a TYK2 inhibitor, to treat adults with moderate to severe plaque psoriasis. (w/ a PDUFA goal date of 9/10/2022) https://t.co/w5YmRYdXm4

Dr. John Cush @RheumNow( View Tweet )

Dec 09, 2021
×